186 related articles for article (PubMed ID: 11299807)
21. Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens.
Kunju LP; You L; Zhang Y; Daignault S; Montie JE; Lee CT
J Urol; 2008 Nov; 180(5):1928-32; discussion 1932. PubMed ID: 18801529
[TBL] [Abstract][Full Text] [Related]
22. Lymphovascular invasion is independently associated with poor prognosis in patients with localized upper urinary tract urothelial carcinoma treated surgically.
Saito K; Kawakami S; Fujii Y; Sakura M; Masuda H; Kihara K
J Urol; 2007 Dec; 178(6):2291-6; discussion 2296. PubMed ID: 17936818
[TBL] [Abstract][Full Text] [Related]
23. The prognostic value of E-cadherin, alpha-, beta- and gamma-catenin in bladder cancer patients who underwent radical cystectomy.
Kashibuchi K; Tomita K; Schalken JA; Kume H; Takeuchi T; Kitamura T
Int J Urol; 2007 Sep; 14(9):789-94. PubMed ID: 17760743
[TBL] [Abstract][Full Text] [Related]
24. Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder.
Karam JA; Shariat SF; Huang HY; Pong RC; Ashfaq R; Shapiro E; Lotan Y; Sagalowsky AI; Wu XR; Hsieh JT
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4400-6. PubMed ID: 17671122
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of the human erythrocyte glucose transporter occurs as a late event in human colorectal carcinogenesis and is associated with an increased incidence of lymph node metastases.
Younes M; Lechago LV; Lechago J
Clin Cancer Res; 1996 Jul; 2(7):1151-4. PubMed ID: 9816281
[TBL] [Abstract][Full Text] [Related]
26. [Cyclooxygenase-2-expression in bladder cancer: tumor-biological and clinical implications].
Wülfing C; Eltze E; Von Struensee D; Wülfing P; Bode ME; Bettendorf O; Piechota H; Hertle L
Aktuelle Urol; 2004 Aug; 35(4):331-8. PubMed ID: 15459875
[TBL] [Abstract][Full Text] [Related]
27. Radical cystectomy and extended pelvic lymphadenectomy: survival of patients with lymph node metastasis above the bifurcation of the common iliac vessels treated with surgery only.
Steven K; Poulsen AL
J Urol; 2007 Oct; 178(4 Pt 1):1218-23; discussion 1223-4. PubMed ID: 17698113
[TBL] [Abstract][Full Text] [Related]
28. [Expression of hypoxia inducible factor-1alpha and glucose transporter protein 1 in renal and bladder cancers and the clinical significance thereof].
Zhou JT; Cai ZM; Li NC; Na YQ
Zhonghua Yi Xue Za Zhi; 2006 Jul; 86(28):1970-4. PubMed ID: 17064593
[TBL] [Abstract][Full Text] [Related]
29. Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival.
Dotan ZA; Kavanagh K; Yossepowitch O; Kaag M; Olgac S; Donat M; Herr HW
J Urol; 2007 Dec; 178(6):2308-12; discussion 2313. PubMed ID: 17936804
[TBL] [Abstract][Full Text] [Related]
30. The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer.
Streeper NM; Simons CM; Konety BR; Muirhead DM; Williams RD; O'Donnell MA; Joudi FN
BJU Int; 2009 Feb; 103(4):475-9. PubMed ID: 18990174
[TBL] [Abstract][Full Text] [Related]
31. Human erythrocyte glucose transporter (Glut1) is immunohistochemically detected as a late event during malignant progression in Barrett's metaplasia.
Younes M; Ertan A; Lechago LV; Somoano J; Lechago J
Cancer Epidemiol Biomarkers Prev; 1997 May; 6(5):303-5. PubMed ID: 9149888
[TBL] [Abstract][Full Text] [Related]
32. [Usefulness of p53 oncoprotein immunohistochemistry in the follow-up of bladder carcinoma: a 5-year study].
Moreno Sierra J; López García Asenjo JA; Redondo González E; Fernández Pérez C; Maestro de las Casas ML; Blanco Jiménez E; Silmi Moyano A; Resel Estévez L
Arch Esp Urol; 1999 Oct; 52(8):840-8. PubMed ID: 10589115
[TBL] [Abstract][Full Text] [Related]
33. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma.
Zigeuner R; Tsybrovskyy O; Ratschek M; Rehak P; Lipsky K; Langner C
Urology; 2004 Jun; 63(6):1079-83. PubMed ID: 15183954
[TBL] [Abstract][Full Text] [Related]
34. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
[TBL] [Abstract][Full Text] [Related]
35. The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy.
Wright JL; Lin DW; Porter MP
Cancer; 2008 Jun; 112(11):2401-8. PubMed ID: 18383515
[TBL] [Abstract][Full Text] [Related]
36. Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder.
Dalbagni G; Parekh DJ; Ben-Porat L; Potenzoni M; Herr HW; Reuter VE
BJU Int; 2007 Feb; 99(2):281-5. PubMed ID: 17155984
[TBL] [Abstract][Full Text] [Related]
37. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
[TBL] [Abstract][Full Text] [Related]
38. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach.
Garcia del Muro X; Condom E; Vigués F; Castellsagué X; Figueras A; Muñoz J; Solá J; Soler T; Capellà G; Germà JR
Cancer; 2004 May; 100(9):1859-67. PubMed ID: 15112266
[TBL] [Abstract][Full Text] [Related]
39. Serum tumor markers may predict overall and disease specific survival in patients with clinically organ confined invasive bladder cancer.
Margel D; Tal R; Baniel J
J Urol; 2007 Dec; 178(6):2297-300; discussion 2300-1. PubMed ID: 17936837
[TBL] [Abstract][Full Text] [Related]
40. Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome.
Kramer C; Klasmeyer K; Bojar H; Schulz WA; Ackermann R; Grimm MO
Cancer; 2007 May; 109(10):2016-24. PubMed ID: 17394193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]